STAT+: Amgen\u2019s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
CHICAGO \u2014 Amgen\u2019s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a mid-stage trial, results that support the company\u2019s decision to use a slower dosing schedule to make the drug more tolerable in further testing.\u00a0<\/p>\n
In the Phase 2 study, patients with obesity taking the injectable drug, called MariTide, lost up to 16.2% of their weight in one year when taking into account all participants regardless of discontinuations. Patients lost up to 19.9% when analyzing only those who stayed on treatment.<\/p>\n
Patients with obesity and type 2 diabetes lost up to 12.3% of their weight when analyzing all participants and up to 17% when analyzing those who didn\u2019t discontinue, according to results that were published<\/a> Monday in the New England Journal of Medicine and will be presented here at the American Diabetes Association meeting.<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n